Educational only. BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, and emideltide are not currently available YourHealthRx offerings. This article does not indicate that YourHealthRx offers, prescribes, dispenses, compounds, ships, or guarantees access to any of them. Nothing here is medical advice, dosing guidance, or a treatment recommendation.
This updates our earlier BPC-157 and TB-500 guides, which treated the July 23–24 meeting as upcoming. The meeting happened. The votes were close. FDA scientists had recommended against inclusion. The legal status has not changed.
Bottom line: A PCAC vote is a recommendation to FDA. It is not a listing, not an approval, and not a green light to compound.
What the July 2026 FDA peptide vote decided
The Pharmacy Compounding Advisory Committee advises FDA on which bulk substances state-licensed 503A pharmacies may use for an identified patient. A yes vote asks FDA to consider a listing. It does not create one.
Over two days the committee reviewed seven peptides. None is FDA-approved. None currently has a lawful 503A pathway.
On July 23, the committee recommended BPC-157, KPV, and TB-500 by 8-6-1 votes, taken separately for free-base and acetate forms. MOTS-c was recommended 7-5-2. On July 24 it recommended Semax and Epitalon by similarly narrow margins, and voted against emideltide (also called DSIP).
FDA’s own reviewers had recommended against all seven, citing limited human evidence, unsettled chemical identity, and safety questions for injectable use. Public-health commenters also warned that a 503A listing would be misread as FDA approval.
Is BPC-157 FDA-approved?
No. BPC-157 is not an FDA-approved drug for recovery, gut conditions, or any other use. The July vote was not a drug-approval decision. Approval requires a clinical program, labeled indications, and manufacturing under current Good Manufacturing Practice.
A future 503A listing, if FDA ever finalizes one, would still be a compounding pathway, not an approval. Those are different bars, and headlines often collapse them.
The same is true for TB-500. It is not FDA-approved. The committee recommended it for possible listing. That does not make it a proven recovery therapy, and it does not make it legal to compound today.
Can compounding pharmacies make BPC-157 or TB-500 now?
Not under a lawful 503A pathway. As of early August 2026, counsel tracking the meeting have been explicit: the recommendations are nonbinding, these substances still cannot be lawfully compounded, and FDA can still take enforcement action against pharmacies that make them.
Grey-market vials labeled “research use only” did not become a regulated clinical product because a committee voted. Sourcing, sterility, identity, and a licensed clinician review still matter more than a headline.
What happens next
FDA now has briefing documents, public comments, and the votes. The ordinary path to a list change is notice-and-comment rulemaking: a proposed rule, a comment period, then a final determination. Legal analyses after the meeting have put that process in a 12-to-24-month range. There is no public final rule as of this writing. FDA is not required to follow the committee.
Until that finishes, two things can be true at once. The committee recommended a path. The path is not open.
Questions to ask before you act on the headline
If someone says “FDA just approved BPC-157,” ask them to separate three things: the advisory recommendation, the current legal status, and the human evidence for your actual goal. If those get collapsed, the explanation is not careful enough.
If a product is being offered, ask whether it comes from a named, state-licensed 503A pharmacy, on a patient-specific prescription, after a clinician reviewed your history. A checkout page and a research-chemical label are not that.
Ask what happens to the plan if FDA does not accept the recommendation, or accepts it only after a long rulemaking. A protocol that depends on a future list change is not a plan.
FAQ
Did the FDA legalize BPC-157 in July 2026?
No. An advisory committee recommended possible inclusion on the 503A Bulks List. That is not legalization.
Is TB-500 legal to compound?
Not today. It received the same kind of advisory recommendation as BPC-157. It is not FDA-approved and it is not on the 503A list.
Does a 503A listing mean a peptide is safe and effective?
No. Listing asks whether a bulk substance may be used in compounding. It does not turn preclinical models or small pilots into Phase 3 outcome data. Our BPC-157 and TB-500 guides still apply.
Does YourHealthRx offer these peptides now?
No. Educational coverage is not a product page. A vote does not change current offerings.
If you want a clinician-reviewed pathway that is available today, start with eligibility. That conversation is about your history, your goals, and what can be prescribed now.
Informational only. This article is educational and does not constitute medical advice, diagnosis, treatment, or a patient-clinician relationship. It is not an offer to provide, prescribe, compound, dispense, or ship any drug or compounded product. Availability of any specific compound depends on applicable law, current FDA status, clinician judgment, and partner pharmacy policy. Regulatory questions should be reviewed with a qualified healthcare attorney.
Sources: Holland & Knight, August 4, 2026 · FDA Law Blog, July 24, 2026 · RAPS / Regulatory Focus, July 24, 2026 · AJMC meeting recap